

Home » Diseases, Conditions, Syndromes » March 12, 2014

New and extremely promising antibiotic for tuberculosis

Even though tuberculosis kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.

Proteins, Abs for Cancer Research

Premium Quality

Save up to 50%

Order Now!



SB Sino Biological Inc.
Biological Solution Specialist

▶ Researchers from EPFL and the AN Bach Institute in Moscow have discovered a new and extremely promising antibiotic for tuberculosis, especially effective against multi-resistant strains of the disease, which are on the rise in Eastern Europe. The drug, developed as a European FP7 project, has proven very effective against the disease. In an article published in *EMBO Molecular Medicine*, the researchers show that, when combined with other drugs, the new antibiotic, called "PBTZ169", can take down even the most resistant strains of tuberculosis bacteria. Following the publication, the researchers formed the IM4TB Foundation on their campus.

Supported by EPFL, the foundation aims to bring the new treatment to the market. This unusual step was taken because traditionally, technology transfer from academia to the pharmaceutical industry doesn't work well with tuberculosis: development costs are too high and the affected countries are often barely able to maintain their own healthcare infrastructures.

With the IM4TB Foundation, EPFL intends to pick up the slack in the limitations of the industrial model. "The development of antibiotics is increasingly expensive and the countries most affected by tuberculosis are still emergent," says Benoit Lechartier, co-author of the PBTZ169 study. "The recent closure of the AstraZeneca research center in India illustrates the extent to which it is difficult for the pharmaceutical industry to invest in infectious diseases."

Human trials in 2015

Located on the EPFL campus, the IM4TB Foundation plans to move onto human trials within a year, in collaboration with the University of Lausanne Hospitals (CHUV).

PBTZ169 shows much promise. It attacks the bacterium's strong point – the cell wall, which forms an impenetrable shield against antibiotics and the patient's immune system. "Our molecule makes the bacterium literally burst open," explains Stewart Cole, director of the study and head of EPFL's Global Health Institute.

Wirkung von Ingwer:

fid-gesundheitswissen.de/ingwer


Wie Sie mit Ingwer Ihre Beschwerden ohne aggressive Chemie loswerden



A cheap but formidable weapon against resistant strains

The researchers showed that PBTZ169 is extremely effective in tri-therapy, where it is combined with a standard drug, pyrazinamide, and a more recent one, bedaquiline – and both these drugs have already been approved by the EU and the FDA for multi-resistant strains. "This could be the winning strategy", says Cole. "These molecules attack different targets in the bacterium. By combining them, we drastically reduce the risk that it will mutate into more resistant forms."

As a treatment, PBTZ169 has many advantages. It is not expensive to produce, since it is relatively easy to synthesize. Initial tests have shown good compatibility with other



Featured
Popular
Most shared

[Unique individual demonstrates desired immune response to HIV virus](#) Mar 10, 2014 1

 [Scientists unlock potential heart attack drug without side effects](#) Mar 11, 2014 0

 [Self-acceptance could be the key to a happier life](#) Mar 10, 2014 2

 [New gene for bipolar disorder discovered](#) Mar 11, 2014 0

 [Several FDA-approved anti-cancer drugs induce stem cell tumors, perhaps thwarting therapy](#) Mar 10, 2014 0

Medical Xpress on facebook

 Like 21,206 people like this. Be the first of your friends.

MedicalXpress.com


 Follow +1

+ 1,656

anti-tuberculosis treatments and it is expected to be equally compatible with antiretrovirals used to treat AIDS, as HIV-positive individuals are particularly vulnerable to [tuberculosis](#), and cases of cross-infection are on the rise.

This molecule is the culmination of many years of research. The preliminary versions were formidable in the laboratory, where they decimated bacteria in culture. However, their effectiveness in vivo was limited. New technologies like structural biology enabled researchers to redesign the molecule so that it could be more rapidly absorbed. "Thus we were able to improve its pharmacodynamics," explains Cole. "Tuberculosis is often wrongly considered a disease of the past, but in order to fight it, we needed to employ 21st century technologies."

More than 1.5 million deaths per year

Tuberculosis still kills more than 1.5 million people every year. It is uncommon in Europe, although certain countries such as the Ukraine are experiencing a resurgence of patients infected with multiresistant strains. The EU is leading a program that aims to eliminate the disease. The research team at EPFL that developed PBTZ169 received funding from the Seventh Framework Programme (FP7) of the European Commission, in the framework of an international collaboration.

Explore further: [Tuberculosis: Nature has a double-duty antibiotic up her sleeve](#)

More information: "Towards a new combination therapy for tuberculosis with next generation benzothiazinones." Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST. *EMBO Mol Med.* 2014 Mar 1;6(3):372-83. DOI: [10.1002/emmm.201303575](#). Epub 2014 Feb 5.

Journal reference: [EMBO Molecular Medicine](#)




Provided by [Ecole Polytechnique Federale de Lausanne](#)

5 / 5 (1 vote)

1
 0
 4

Try brain training tested by dozens of researchers



lumosity

Start Training →

Related Stories

[Tuberculosis: Nature has a double-duty antibiotic up her sleeve](#)

Dec 03, 2013

Technology has made it possible to synthesize increasingly targeted drugs. But scientists still have much to learn from Mother Nature. Pyridomycin, a substance produced by non-pathogenic soil bacteria, has been found to be ...

Recommended for you

[Newly diagnosed Crohn's disease patients show imbalance in intestinal microbial population](#) 25 minutes ago

A multi-institutional study led by investigators from Massachusetts General Hospital (MGH) and the Broad Institute has identified how the intestinal microbial population of newly diagnosed Crohn's disease patients differs ...

[Scientists reveal how natural antibiotic kills tuberculosis bacterium](#) Sep 17, 2012

A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown ...



[Imbalanced hearing is more than a mild disability](#)

2 hours ago

Researchers at Washington University School of Medicine in St. Louis have received a five-year, \$3 million grant from the National Institutes of Health (NIH) to study the effects of asymmetric hearing loss ...

[Promising class of antibiotics discovered for treatment of drug-](#)

resistant tuberculosis  Mar 05, 2014

St. Jude Children's Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis

Misery mounts in drought-hit southeast Pakistan (Update)  Mar 11, 2014

User comments

Please [sign in](#) to add a comment. Registration is free, and takes less than a minute. [Read more](#)

[Sign In](#)

[Click here](#) to reset your password.
Sign in to get notified via email when new comments are made.

- [top](#)
- [Home](#)
- [Search](#)
- [Help](#)
- [About us](#)
- [FAQ](#)
- [Contact](#)
- [Science X Account](#)
- [Sponsored Account](#)
- [Newsletter](#)
- [RSS feeds](#)







[Privacy Policy](#)
[Terms of use](#)
[Disclaimer](#)

© Medical Xpress 2011-2014, [Science X network](#)